NTLA PEER ANALYSIS

Intellia Therapeutics Inc — metric-by-metric comparison with peers and the industry median

NTLAIntellia Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

NTLAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	NTLA	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	30.02	17.81
P/B	3.40	6.56	—	2.24●	3.49
EV/EBITDA	—	123.31	—	10.37●	14.92
P/S	31.98	3.34	31.91	2.67●	10.89

Financial Health
Metric	NTLA	TLX	MSB	CSL	Ind. Median
Current Ratio	6.10●	1.43	—	2.57	5.90
Debt/Equity	13.0%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	0.77●	13.13	—	2.22	1.15

Profitability
Metric	NTLA	TLX	MSB	CSL	Ind. Median
Net Margin	-597.0%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-56.3%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-45.2%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	-581.9%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	NTLA	TLX	MSB	CSL	Ind. Median
Rev. Growth	45.0%	56.3%	410.4%●	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	NTLA	STOK	ADMA	AUPH	NUVB	RXRX	Ind. Median
P/E	—	—	13.29	7.15●	—	—	17.81
P/B	3.40	5.18	5.63	3.76	6.62	2.05●	3.49
EV/EBITDA	—	—	10.22●	11.26	—	—	14.92
P/S	31.98	63.75	4.31●	7.15	14.78	31.62	10.89

Financial Health
Metric	NTLA	STOK	ADMA	AUPH	NUVB	RXRX	Ind. Median
Current Ratio	6.10	8.99●	6.95	5.55	7.44	5.47	5.90
Debt/Equity	13.0%	0.9%●	52.4%	12.1%	3.1%	7.1%	10.9%
NetDebt/EBITDA	0.77	2.07	0.30	-1.92●	4.04	1.21	1.15

Profitability
Metric	NTLA	STOK	ADMA	AUPH	NUVB	RXRX	Ind. Median
Net Margin	-597.0%	-529.2%	32.4%	100.0%●	-102.1%	-844.5%	-125.7%
ROE	-56.3%	-45.6%	43.3%	65.0%●	-39.5%	-57.2%	-47.5%
ROA	-45.2%	-39.9%	28.1%	48.5%●	-26.5%	-42.3%	-35.8%
EBITDA Margin	-581.9%	-511.5%	43.4%	54.2%●	-90.7%	-723.3%	-105.8%

Growth + Dividend
Metric	NTLA	STOK	ADMA	AUPH	NUVB	RXRX	Ind. Median
Rev. Growth	45.0%	-83.2%	11.0%	20.6%	1,205.5%●	11.0%	5.1%
NI Growth	—	—	-20.0%	648.4%●	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on NTLA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.